Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Jan;100(1):239-259.
doi: 10.1007/s00277-020-04286-x. Epub 2020 Sep 30.

Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Boris Böll  1 , Enrico Schalk  2 , Dieter Buchheidt  3 , Justin Hasenkamp  4 , Michael Kiehl  5 , Til Ramon Kiderlen  6 , Matthias Kochanek  7 , Michael Koldehoff  8 , Philippe Kostrewa  9 , Annika Y Claßen  7 , Sibylle C Mellinghoff  7 , Bernd Metzner  10 , Olaf Penack  11 , Markus Ruhnke  12 , Maria J G T Vehreschild  13 , Florian Weissinger  14 , Hans-Heinrich Wolf  15 , Meinolf Karthaus  16 , Marcus Hentrich  17
Affiliations
Review

Central venous catheter-related infections in hematology and oncology: 2020 updated guidelines on diagnosis, management, and prevention by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)

Boris Böll et al. Ann Hematol. 2021 Jan.

Abstract

Cancer patients frequently require central venous catheters for therapy and parenteral nutrition and are at high risk of central venous catheter-related infections (CRIs). Moreover, CRIs prolong hospitalization, cause an excess in resource utilization and treatment cost, often delay anti-cancer treatment, and are associated with a significant increase in mortality in cancer patients. We therefore summoned a panel of experts by the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) and updated our previous guideline on CRIs in cancer patients. After conducting systematic literature searches on PubMed, Medline, and Cochrane databases, video- and meeting-based consensus discussions were held. In the presented guideline, we summarize recommendations on definition, diagnosis, management, and prevention of CRIs in cancer patients including the grading of strength of recommendations and the respective levels of evidence. This guideline supports clinicians and researchers alike in the evidence-based decision-making in the management of CRIs in cancer patients.

Keywords: CLABSI; CRBSI; Cancer; Catheter infection; Central venous catheter; Neutropenia.

PubMed Disclaimer

Conflict of interest statement

Boris Böll received grants from Astra Zeneca and Sanofi; personal fees from Celgene, MSD, Roche, and Takeda; and personal fees from Baxalta, Mundipharma, and J&J outside the submitted work.

Dieter Buchheidt received research grants from Gilead Sciences and Pfizer; served on the speakers’ bureau of Gilead Sciences, Merck Sharp & Dohme/Merck, and Pfizer; and received travel grants from Gilead Sciences, Merck Sharp & Dohme/Merck, and Pfizer, outside the submitted work.

Justin Hasenkamp received honoraria as a consultant from AMGEN, Bristol-Myers Squibb, Celgene, Gilead Science, Jazz Pharmaceuticals, MSD Sharp & Dohme, Neovii, Novartis Pharma, and Mundipharma and payment for educational presentations (written or oral) from Deutscher Ärzte-Verlag, Georg Thieme Verlag, MedKom Akademie, and NewConceptOncology GmbH outside the submitted work.

Michael Koldehoff received lecture honoraria from CSL Behring and AURIKAMED outside the submitted work.

Olaf Penack has received honoraria and travel support from Astellas, Gilead, Jazz, MSD, Neovii Biotech, and Pfizer. He has received research support from Bio Rad, Gilead, Incyte, Jazz, Neovii Biotech, Pierre Fabre, Sanofi, and Takeda. He is a member of the advisory board to Jazz, Gilead, MSD, Omeros, and SOBI.

Markus Ruhnke was a consultant to Basilea, Daiichi Sankyo, Kedplasma, Janssen, and Scynexis and received payment for development of educational presentations from Basilea and Janssen.

Matthias Kochanek received lecture honoraria from Astellas, Gilead, MSD, and Pfizer outside the submitted work.

Sibylle C. Mellinghoff was a consultant to Octapharma. She has received research funding by the DMyKG, the German Centre for Infection Research, and the University Hospital of Cologne.

All other authors declare no potential competing interests.

Figures

Fig. 1
Fig. 1
Diagnostic procedures in case of suspected catheter-related infection (CRI)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49:1–45. doi: 10.1086/599376. - DOI - PMC - PubMed
    1. Raad I, Chaftari AM. Advances in prevention and management of central line-associated bloodstream infections in patients with cancer. Clin Infect Dis. 2014;59:S340–S343. doi: 10.1093/cid/ciu670. - DOI - PubMed
    1. Gallieni M, Pittiruti M, Biffi R. Vascular access in oncology patients. CA Cancer J Clin. 2008;58:323–346. doi: 10.3322/ca.2008.0015. - DOI - PubMed
    1. Aghdassi SJS, Schröder C, Gruhl D, et al. Point prevalence survey of peripheral venous catheter usage in a large tertiary care university hospital in Germany. Antimicrob Resist Infect Control. 2019;8:1–7. doi: 10.1186/s13756-019-0468-8. - DOI - PMC - PubMed
    1. Baier C, Linke L, Eder M, et al. Incidence, risk factors and healthcare costs of central line-associated nosocomial bloodstream infections in hematologic and oncologic patients. PLoS One. 2020;15:1–11. doi: 10.1371/journal.pone.0227772. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources